<SEC-DOCUMENT>0001193125-24-037291.txt : 20240215
<SEC-HEADER>0001193125-24-037291.hdr.sgml : 20240215
<ACCEPTANCE-DATETIME>20240215120949
ACCESSION NUMBER:		0001193125-24-037291
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240215
FILED AS OF DATE:		20240215
DATE AS OF CHANGE:		20240215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		24642900

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d783000d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of February 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or
Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;&#8195;Form <FONT
STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">In February 2024, Sanofi published the press release attached hereto as Exhibit 99.1 which is
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><U>Exhibit&nbsp;No.</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>Description</U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d783000dex991.htm">Press Release dated February&nbsp;5, 2024: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
</A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Dated: February&nbsp;15, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">SANOFI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">By&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman" ALIGN="justify">/s/ Alexandra Roger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">&#8195;&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Name: Alexandra Roger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title: Head of Legal Corporate&nbsp;&amp; Finance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d783000dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:14pt"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g783000g44r63.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Peer support, flexible work arrangements, salary for a year: Sanofi launches global
program for employees affected by cancer and critical illnesses </I></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Paris, February</B><B></B><B>&nbsp;5, 2024</B>. Sanofi today launches
<B>&#145;Cancer</B><B></B><B>&nbsp;&amp; Work: Acting Together&#146;</B>, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses. This program covers all Sanofi employees in the world if they are
diagnosed with cancer or critical illnesses*. It provides <B>social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter the role or geographical location.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Natalie Bickford </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Chief People Officer, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<I>Many of us will face cancer one way or another in our lives. The last thing you want to be thinking
about when you are diagnosed with cancer, or going through treatment, is work. And yet, half of people who receive a cancer diagnosis are frightened to tell their workplace. That is not right. I am delighted that Sanofi has gone beyond its
commitment to provide job security and salary continuation for at least a year after diagnosis. Today, we also support every Sanofi employee facing cancer by training a global network of affinity groups who can provide safe spaces, and by helping
managers understand the challenges their team members may be facing, and how best to approach them for reassurance and support</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">On top of
financial support, employees will be able to incorporate further flexible work arrangements to better navigate cancer and work. The program also addresses the emotional wellbeing of Sanofi employees impacted by cancer and other critical illnesses.
They will have access to a network of volunteer colleagues trained to help them navigate from initial diagnosis through the treatment journey and return to work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Many of the volunteers in the network have experienced cancer; connecting with them creates a safe space for sharing experiences, discussing accessible
resources and building supportive relationships. Impacted employees have also access to an external psychological support in all countries 24/7 through the Employee Assistance Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition, throughout 2024, Sanofi intends to implement coverage of miscellaneous <FONT STYLE="white-space:nowrap">non-medical</FONT> expenses.<B>
</B>Moreover, Sanofi permanent employees will become eligible for an unpaid caregiver leave which allows them to carry out caregiving duties for their close family member suffering from a critical illness*. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The program<B> </B>is also designed to better equip managers to support members of their team who are affected by cancer. It connects them with the
knowledge they will need to take that first step in helping a colleague navigate their local benefit and support programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>A
global program inspired by an employee initiative </I></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In 2017, several volunteer employees in France, with complementary expert skills and
experience as patients, caregivers or managers, started the initiative. They first created space for affected employees to share their experience, ask questions, and hear from colleagues who have been through similar situations and found ways to
reconcile work and illness. Importantly, they helped develop the right support the affected employee needs within their team. These groups can be called upon at any time, when learning the diagnosis, during treatment, during leaves, upon return to
work, and in the years that follow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g783000g86v74.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The program has since grown to a network of 27 partner teams with one team at each Sanofi site in
France, with 150 members who share feedback and best practice. More than 350 employees have benefited (42% sick employees, 30% caregivers, 28% managers). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The global program announced today echoes the original approach and makes Sanofi an ever more inclusive culture where everyday experiences matter for
every employee worldwide. This wraps the program into a wider DE&amp;I cultural transformation at Sanofi as the company drives Diversity, Equity, and Inclusion (DE&amp;I) in and beyond the workplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Global impact of cancer and work </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Of all chronic conditions, cancer had the highest prevalence of work loss. Research shows that the risk of losing a person&#146;s job in the EU
increases 1.4 times after a cancer diagnosis<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>. According to an article published in the Journal of the National Cancer Institute, cancer-related employment changes are experienced by more than 40%
of cancer survivors who were employed at or after diagnosis in the US<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Worldwide, the number
of people diagnosed with cancer who are of working age is significant. For example, around 45% of people diagnosed in the U.S. in 2020 were between 20&#150;64 years old<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>. In France, around
160,&nbsp;000 of the 400,000 people newly diagnosed with cancer were of working age and in the UK, around 900,000 people of working age are living with cancer. In a recent Harris poll conducted last year in the U.S. by Cancer&nbsp;&amp; Careers, 35%
said that in general, those with cancer face stigma in the workplace. Yet, that same study revealed 78% felt that people who have been diagnosed with cancer and receive support from their employer are more likely to thrive in the workplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi DE&amp;I strategy </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Sanofi&#146;s ambitious DE&amp;I strategy was launched in June 2021 with set objectives toward 2025, built around three key pillars: building
representative leadership, creating a work environment where employees can bring the best of their whole selves and engaging with the company&#146;s diverse communities. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Read more information on Sanofi&#146;s DE&amp;I strategy&nbsp;<FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#7a00e6"><U>here</U></FONT><FONT
STYLE="font-family:ARIAL">. </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #cccccc">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We are
an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sandrine
Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Timothy Gilbert</B> |
+ 1 516 521 2929 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nicolas Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sally Bain</B><B></B>&nbsp;|&nbsp;+ 1 617 834 6026 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>sally.bain@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="justify"><SUP
STYLE="font-size:75%; vertical-align:top">* </SUP>Specific criteria identifying the conditions and circumstances that are eligible for coverage under this program might be governed by the terms and conditions of country-specific policies or legal
requirements. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="justify"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> <U>Cancer survivors and unemployment: a meta-analysis and meta-regression -
PubMed (nih.gov)</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="justify"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP> <U>Employment Outcomes Among Cancer Survivors in the United States:
Implications for Cancer Care Delivery | JNCI: Journal of the National Cancer Institute | Oxford Academic (oup.com)</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="justify"><SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> Binder, V. Gany, F., (2020) Impact of Cancer on Employment. Journal of Clinical Oncology, 2020 Feb 1; 38(4): <FONT STYLE="white-space:nowrap">302-309.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g783000g86v74.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Eva Schaefer-Jansen</B><B></B>&nbsp;|&nbsp;+ 33 7 86 80 56 39
|&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>eva.schaefer-jansen@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Arnaud
Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Corentine Driancourt</B><B></B>&nbsp;|&nbsp;+ 33 6 40 56 92 21 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>corentine.driancourt@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Felix
Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Tarik Elgoutni|</B> + 1 617 710 3587 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g783000g86v74.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g783000g44r63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g783000g44r63.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M.T\'W7P^US4=,?2=,UN;5K?4[:R\-V?B".9+FZT^V>UG8SRP%2DBC8C@\E0
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M^"NIZM<3^$/&EC'->PZ18W<\DMEX>\5R1H6TO6;2,K;B>8)!>B)9H'WO)#
M<?X0_P""@7[8/@;P];^%]!^.'B<Z190):V*:S;Z+XCO;*VB01Q06VJ>(-,O+
MQ(8XPJHAG*HJA5   HV#8^?]9UGXJ_'CQY/JVKW7C#XI?$/Q)-!&\QBU'Q'X
M@U%XTCMK2V@M[:.67R(HEBBB@AC6.)%5$55   /Z]OV"OAOXP^$G[)/P=\ ^
M/M(ET'Q;H^F>([O5M&G>-[G3#X@\:>)/$=C:7?E,RQ7J:=J]GYT6XF*7?&WS
M(:-O(-O(_DV_:B!7]IC]H@$%2/CG\6>",$?\5[K_ &- ']J/PT!7X<?#\$%2
MO@GPH"",$$:%8 @CL10!^"'_  7#!'C/]GLX(!\,>/P#C )75?#)(!]0"/S'
MK0!]&_\ !$T$?L]?%(X(!^,UV <8!(\$>#L@'U&1^8H YG_@J!^P'XH^*FK?
M\-"?!'0SK7B^+38;+XC>"].C4:KXCMM+A6'3?$^A6X .HZU;V$<=E=62DRW$
M%I9M;H\T4B3GZ!^A^)7PG_:<_:+_ &<6U/0OAK\1/%'@>W:]E.K>%[B*"[TN
M+4XCY,\D_AW7[.YMK+4@8Q')(MO%,?*"R$[  ;!L9?C'XC?'[]JGQSHT/BK7
MO&?Q;\:W<@TSPYH\<4M^]O\ :Y8]]IH>A:9 EKIL,DHC:4VUO"IV!Y6^3< #
M^FW_ ()S?L8W7[*7PXU;4_'$>FS_ !=^(4MG=>)7L9$O(O#6A64>[2?"-M?A
M=L\T-Q-=75]-;GR9;B:.-&FCL(9I#8-C\O?^"V@(^/?PG."!_P *A0 ]!D>,
M_$^0#ZC(_,4 ?H+_ ,$<P1^R'<<$ _%CQH5R,9 TWPP,CVR"/P- 'Z5^/03X
M%\:*H))\)^(PJ@9))T>\   [YH _B8_9M!/[1/P#5023\:?A: H&23_PG.A8
M  [T ?T?:?\ \GRS_P#8=N?YR5_5%?\ Y,=#_L$A_P"VGZ54_P"2-C_UZ7YH
M_56OY7/S4_.O]I[_ )*:?^Q?TK_T.[H ^PO@I_R2SP9_V#)/_2Z[H ZCQO\
M\BCXA_[!5W_Z+- '\I'Q6_Y*+J7_ &$[C_T>U '[A?\ !/[_ )%>\_Z]X/\
MT T ?H_0!^6?Q5_Y*QXM_P"QFF_]')0!^HUO_J(/^N,?_H"T ?'_ .UO_P >
MG@C_ *^=<_\ 16FT =S^R]_R36;_ +&35/\ TGT^@#Z-H _ C_@I5_R47_M@
MG_H1H ^A_P#@F%_R!_$?_7.#_P!!- 'ZX4 ?$?[6O_(2\&?]>.J_^E%I0![1
M^SE_R2G1/^OW6/\ TY7% 'N,G^KD_P!QO_030!^6'PO_ .2J>$/^QJL__2J@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g783000g86v74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g783000g86v74.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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FC^*XNK2PNKFVMY&T_P 8;8YIX8F2)SYD>%9@3O7U%&WD&WD?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
